EP1117328B1 - Methods, systems, and associated implantable devices for dynamic monitoring of tumors - Google Patents

Methods, systems, and associated implantable devices for dynamic monitoring of tumors Download PDF

Info

Publication number
EP1117328B1
EP1117328B1 EP99950017A EP99950017A EP1117328B1 EP 1117328 B1 EP1117328 B1 EP 1117328B1 EP 99950017 A EP99950017 A EP 99950017A EP 99950017 A EP99950017 A EP 99950017A EP 1117328 B1 EP1117328 B1 EP 1117328B1
Authority
EP
European Patent Office
Prior art keywords
tumor
treatment
sensor
radiation
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99950017A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1117328A1 (en
Inventor
Charles W. Scarantino
H. Troy Nagle
Leslie C. Hall
Jeffrey Mueller
Bahram Ghaffarzadeh Dr. Kermani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
University of California
Sicel Technologies Inc
Original Assignee
North Carolina State University
University of California
Sicel Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, University of California, Sicel Technologies Inc filed Critical North Carolina State University
Priority to EP07016983A priority Critical patent/EP1867275B1/en
Priority to DK07016983.4T priority patent/DK1867275T3/da
Publication of EP1117328A1 publication Critical patent/EP1117328A1/en
Application granted granted Critical
Publication of EP1117328B1 publication Critical patent/EP1117328B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0031—Implanted circuitry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495—Calibrating or testing of in-vivo probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/08—Sensors provided with means for identification, e.g. barcodes or memory chips
    • A61B2562/085—Sensors provided with means for identification, e.g. barcodes or memory chips combined with means for recording calibration data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1071—Monitoring, verifying, controlling systems and methods for verifying the dose delivered by the treatment plan

Definitions

  • This invention relates to diagnostic medical instruments and procedures, and more particularly to implantable devices and methods for monitoring physiological parameters.
  • the most reliable current monitoring technique is the biopsy.
  • a biopsy can be taken at any time and can provide significant amount of information.
  • it is impractical to biopsy each day and, even if one could, the time delay created in performing the various tests on the sample means that the information received by the physician is not an accurate representation of the patient's current condition.
  • the radiological techniques ofNMR and PET scanning can obtain, respectively, specific biological (cell cycle phase) and physiological (phosphorus) information, but both are sufficiently expensive that repetitive or daily information is rarely available.
  • the radioactive labeling of specific antibodies or ligands is another available technique, but this method has many of the same problems noted above with the other assays.
  • tumor pH has been suggested as an exploitable parameter for drug design for tumor treatments, See Leo E. Gerweck, "Tumor pH: Implications for Treatment and Novel Drug Design", 8 Seminars in Radiation Oncology No. 5. pp. 176-182 (July 1998 ).
  • EP 0 420 177 A1 proposes an apparatus for the wireless measurement in the living body of a local physical quantity such as temperature or pressure.
  • the reference also discusses measuring temperature at various points in human tumor tissue with the application of hyperthermia procedures for cancer therapy to provide a temperature distribution for registration of the temperature in the core of the tumor and its edge areas.
  • the reference also states that it is possible to use several transponders to wirelessly monitor, on an on-going basis, pulse, EKG, blood pressure and body temperature of one or more humans or animals which are located within the effective range of the control devices.
  • tumor monitoring systems and/or sensors used to monitor tumors can be exposed to a relatively harsh environment during a treatment protocol or strategy which can extend over a period of weeks, or even months (such as applied heat, chemicals and/or radiation). Further, such a harsh environment, coupled with an extended treatment period, can affect the function of the device and thus, potentially corrupt the measurement data it generates.
  • tumor monitoring systems and devices which can, inter alia, monitor the physiological and/or biological condition of a tumor during a treatment cycle to identify enhanced or favorable treatments windows to potentially increase in vivo treatment efficacy associated with such treatment.
  • FIG. 8 is an additional aim of embodiments of the present invention to provide a system for monitoring tumors which can indicate (in substantially real time) whether conditions are favorable or unfavorable for an active treatment such as drug delivery, hyperthermia, chemotherapy, or radiation therapy.
  • Ii is still another aim of embodiments of the present invention to provide a system for analyzing a plurality of measurements generated by at least one implanted sensor and analyzing the measurements and identifying the presence or absence of one or more predetermined conditions associated with the measurements to alert the clinician of the existence of a potentially vulnerable and desired treatment phase for a tumor.
  • a biotelemetry based tumor monitoring system with in vivo, in situ sensors positioned to monitor multiple selected parameters representative of the status of a tumor or tumors in a subject.
  • a method of operating a system that monitors and evaluates the status of a tumor site undergoing treatment comprising operational steps of:
  • the transmitting and analyzing steps are repeated sufficiently often (such as at least every 24 hours, and more preferably at least hourly, at least during particular time segments of treatment) to track variation in at least one monitored parameter and thereby assess the behavior of the tumor over time.
  • at least one parameter is a plurality of parameters
  • the analyzing step defines a plurality of test conditions associated with the monitored parameters to evaluate the treatment corresponding to the condition of the tumor (such as the efficacy of treatment or the presence or absence of favorable indices of treatment).
  • a clinician can then be alerted as to the presence of at least one of a favorable and unfavorable treatment window for delivering a subsequent active treatment to the tumor.
  • the favorable treatment window corresponds to the identification of a tumor susceptibility or vulnerability phase.
  • the transmitting step comprises transmitting data from the home site of the patient to a remote clinical site thereby allowing real-time remote dynamic monitoring of the physiological parameter. Further, it is also preferred that the transmitting step is repeated temporally proximate to a subsequent active treatment delivery time to provide real-time information regarding the desirability of the timing of a planned treatment or the efficacy of a delivered treatments.
  • the present invention now allows targeted tumor treatment directed by the response or behavior of the malignant cells of a tumor itself as well as the response of the normal cells proximate to the tumor(s). Further, the present invention allows both real-time treatment information during active therapy sessions as well as dynamic tacking during Non-active periods. Indeed, a patient can transmit or communicate the monitored parameters on a regular basis with a clinical site via implantable telemetry based sensing devices and home base receivers (such as even multiple times in a 24 hot period) in a relatively cost-efficient manner. This ongoing communication can download real-time information regarding the state of the tumor to a clinical monitoring station.
  • the dynamic tracking can identify relative changes in the tumor and/or absolute values associated with a positive or negative reaction to therapy. This reaction tracking can allow for more proactive therapeutic decisions based on the tumor's response to the treatment.
  • the dynamic tracking can also be used to identify the onset or predict a potentially vulnerable phase of a tumor to allow more effective timing of treatment regimes corresponding to the actual behavior of the tumor.
  • the sensors are positioned at more than one location in the tumor (surface and at a penetration depth), and more preferably at more than one region (over the volume or surface area) associated with the tumor(s) to be able to quantify the tumors overall response to therapy.
  • the systems, methods, and devices of the present invention can monitor, in real time and/or dynamically, specific indices associated with tumor physiology making them available for immediate use in treatment decisions.
  • the instant invention can lead to more definitive and patient-specific treatment protocols, increase tumor response, decrease treatment morbidity, and improve and/or replace assays predicting tumor response, resistance and sensitivity.
  • the present invention can provide information not previously readily available for commercial clinical applications which will likely open new fields of research and therapeutics.
  • the device is particularly suitable for oncology applications.
  • the systems, devices, and methods of the present invention are aimed at monitoring the changes in physiology and kinetics of living systems. More specifically, the present invention's goal is to monitor at sufficient intervals (preferably semi-continuously, and more preferably substantially continuously) the changes in oxygen, pH, and cell proliferation of any organ or tumor system under "normal" physiological conditions, in-situ, as well as prior to, during and following any perturbation (such as radiation, chemical or cytotoxic stimuli and hyperthermia) of such systems.
  • the monitoring systems and methods of the present invention can be useful in many applications, such as, for example, pulmonary, gastrointestinal, neuroscience and pre-clinical research. Nonetheless, the present invention has a particular importance and suitability to tumor systems. As such, the following description of preferred embodiments will primarily discuss the utilization of the present invention for cancer applications.
  • the major goal of cancer therapy is to eliminate all tumor cells. Knowledge of the specific change occurring within the tumor at substantially any time can be desirable in order to achieve maximum tumor cell kill and minimum normal tissue damage. Cytotoxic agents are most effective at specific times and conditions of tumor growth. If the most vulnerable time of the tumor cells can be determined, i.e., the time of maximum oxygenation or identification of an increase in cell proliferation associated with phases of the cell cycle, then this information can be used to direct the time of delivery and the choice of the cytotoxic agents.
  • tumor parameters include one or more of, but are not limited to, the degree of oxygenation, pH, cell cycle phases, cell proliferation, and the molecular and cellular determinants of sensitivity or resistance to cytotoxic agents.
  • the present invention recognizes that the availability of such information and the ability to act upon such information can provide the means of overcoming a major barrier to improvements in outcome in cancer therapy. Further, it is believed that this newly provided information can create a shift in the therapeutic paradigm from empirical to individual based therapy which can rely (at least in part) on the molecular and cellular properties of the individual patient's tumor.
  • the present invention now can provide information on the changes occurring during and after therapy which can be utilized to direct therapy and/or to monitor the effects of the therapy.
  • This individualization of therapy can not only improve outcome but also decrease toxicity and morbidity of the treatment. That is, the information obtained on each patient's tumor can radically change the scheduling of therapy and result in an improved outcome.
  • patients can now be monitored from home, through telephone lines or some other remote interface, to determine a favorable or most appropriate time for treatment
  • the present invention is primarily directed to the in vivo evaluation and monitoring of tumors prior to, during, and subsequent to an active treatment, and preferably over an entire treatment regime or period. That is, the present invention is particularly suitable for monitoring the behavior of cancerous tumors such as sarcomas and carcinomas over a particular non-remission treatment period.
  • the internal in situ sensors of the present invention are preferably configured to be biocompatible and provide a service life suitable for episodic treatment evaluation of at least about 4-6 weeks, and more preferably at least about 6-10 weeks, and still more preferably at least about 10-12 weeks, whether exposed to radiation, chemotherapy, heat or ionic electric fields (such as the treatment provided by a Thermotron®) directed to the tumor.
  • the sensors and preferred tumor monitoring parameters will be discussed further below.
  • the tumor monitoring system 10 includes an in situ sensor unit 50 positioned in a subject 20 proximate to a tumor 25 .
  • the sensor unit 50 includes a plurality of sensor elements 51 positioned at different locations on and/or into the tumor 25 . It is preferred that the sensor elements 51 monitor more than one physiological parameter or a selected physiological parameter associated with the tumor at more than one position in, on, or about the tumor as will be discussed further below.
  • the sensor unit 50 is configured with a telemetry link 60 to wirelessly communicate with an externally located receiver 75 .
  • the receiver 75 includes a computer interface 76 and is operably associated with a physician interface module 80 such as a display monitor associated with a central processing unit, computer, or other computer means to allow physician access to the monitored data.
  • a physician interface module 80 such as a display monitor associated with a central processing unit, computer, or other computer means to allow physician access to the monitored data.
  • the physician interface 80 is a laptop or other mobile/portable computer means to allow a physician instant access to the substantially real-time monitored tumor parameters.
  • Figures 2A and 2B illustrate exemplary applications of real-time evaluations according to the present invention.
  • Figure 2A illustrates using the monitored parameter(s) of the tumor during a hyperthermia therapy session (such as via Thermotron ® device) to control the length, power, field strength, or polarity of the treatment.
  • This control can be provided because the real-time monitored data associated with at least one tumor parameter can provide feedback on the actual treatment penetration depth (via temperature or other parameter) at the tumor itself.
  • the information regarding the condition or behavior of the tumor may suggest another treatment would be more beneficial, or even that further treatment would not be beneficial (at that time).
  • the tumor data is monitored to assess whether conditions are favorable or indeed, unfavorable, for the treatment strategy proposed. That is, if a drug therapy is recommended for tumors exhibiting a pH above a certain value, and the data suggests that the tumor pH is below this value, a physician may choose to postpone that particular therapy for a more favorable time. Of course, other parameters, such as an elevated oxygenation level and a phase of increased cell proliferation, may suggest that other therapy would be more advantageous or that the drug therapy should nonetheless proceed. Additional discussion regarding tumor parameters and the relationship to treatment is provided below.
  • Figure 2B illustrates the use of the real-time tumor data, obtained according to the present invention, in a control feedback loop to control one or more of the power, dose, or duration of a hyperthermia and radiation treatment session.
  • the monitored transmitted data is sent to the receiver 75 which then inputs the data into a computer which has a controller directing the actuator 92 and treatment source 91 (which directs the treatment into the patient).
  • the patient 20 is noted as the controlled "plant” in this figure.
  • FIG. 1B illustrates an alternate embodiment of a tumor monitoring system 10'.
  • the tumor monitoring system 10' includes a home receiver unit 75' and a remote interface 78 which communicates with the physician interface 80 (the physician interface shown in this embodiment is a central processing unit).
  • the patient 20 (the dotted line represents the patient being in the house proximate to the receiver 75' ) even when at home can continue to monitor and transmit data to a remote site.
  • the remote interface 78 can provide the communications link between the monitored local data and a remote clinical oversight station.
  • the remote interface 78 can be provided by any number of interface or data load means including a computer modem, a wireless communication system, an internet connection, or telephone connection.
  • the central processing site upon identification of the existence or onset of a favorable condition for treatment, the central processing site can automatically schedule an evaluation appointment or even schedule a treatment session on therapeutic equipment to take advantage of an opportune or favorable treatment window(s).
  • FIG. 3 illustrates a preferred tumor monitoring and treatment evaluation method according to the present invention.
  • At least one (and preferably a plurality of) physiological parameter associated with a tumor in a subject undergoing treatment is monitored ( Block 100 ).
  • Data associated with the at least one physiological parameter is transmitted from an in situ positioned sensor unit 50 to a receiver 75 located external to a subject ( Block 110 ).
  • the data transmission can be remotely transmitted from a non-clinical site (such as at a patient's home) to a clinical site via modem, telephone, wireless communication systems, and the like ( Block 115 ).
  • the transmitted data is then analyzed to determine a condition of the tumor ( Block 120 ) .
  • the monitoring, transmitting, and analyzing steps are repeated at a plurality of sequential points in time ( Block 125 ).
  • the instant invention allows dynamic monitoring (a plurality of sequential points in time).
  • the dynamic tracking to variation in the tumor can yield valuable therapeutic and diagnostic information.
  • the data is transmitted on a periodic basis (such as every 4-24 hours) over a particular treatment period.
  • the data is transmitted in an at least an intermittent manner (although the data may be transmitted in less or more frequent data transmissions) during an entire treatment cycle, typically from about 1-3 months. More preferably, the data is substantially continuously or semi-continuously monitored (every 1-60 minutes, and more preferably every 1-30 minutes) and, at least locally, transmitted. This ongoing (intermittent, semi-continuous, or substantially continuous) monitoring allows the dynamic tracking or monitoring of the physiological parameter(s).
  • the continuous or semi-continuous monitoring/transmitting can be performed locally for electronic storage within memory associated with the receiver/computer interface 75 ' and then subsequently transmitted (to a central monitoring site on a less frequent basis, such as hourly, daily, and the like). It may be beneficial to preset a data transmittal/acquisition time via a timer in communication with the receiver 75' corresponding to a physician's input (e.g ., more frequent monitoring closer in time to the introduction of cytoxic agents or pertubation, such as every 1-5 minutes, with less frequent monitoring subsequent thereto, such as every 10-15 minutes, or hourly).
  • the data monitoring/transmitting or acquisition time may be self-adjusting and relatively set such as by comparing and reviewing the transmitted data periodically to determine rates of change upon which to institute a more frequent assessment, then transmit less frequently during times of less change in the values.
  • the patient needs to be in proximate position with the receiver 75' to facilitate proper data transmittal.
  • the receiver 75' is preferably configured to generate an alert or alarm when a desired monitoring transmittal time is approaching. This can remind a subject to approach the receiver for proper transmission therebetween.
  • the receiver 75' can be programmed to audibly state the next transmitting time based on the values of the most recently transmitted data while the more current transmittal is still underway (or on the change between a series of more recent transmittals).
  • the receiver 75' can be configured to be portable and sufficiently light weight to allow a user to wear it (attached to clothing or other supporting belts or suspenders or the like) such that it is in a desired proximity to the imbedded sensor unit(s) 50 to more easily provide semi-continuous or substantially continuous dynamic data tracking.
  • the portable receiver unit (not shown) is self-powered with a trickle charger (to plug into a vehicle accessory power source or a wall outlet in the home) to allow a user to recharge the unit when not mobile. It is also preferred that the portable unit be configured with sufficient memory to be able to store a block of data over a period of time before uploading to the remote interface, or directly to a computer interface at a clinical site.
  • a tumor treatment strategy can be evaluated based on the dynamic information provided by the monitored parameter(s) ( Block 130 ).
  • This evaluation can result in a verification of the efficacy of a treatment ( Block 132 ) such as, for example, to determine whether the tumor is responding or resistant to the treatment. Further, the evaluation can verify that a given active dose was received at the tumor and in what amount.
  • One example is to quantify the amount of radiation seen or received at the tumor (this can be helpful if the tumor is blocked by dense tissue or is irregularly configured or positioned in the body in hard to reach regions).
  • This verification may also be particularly suitable for use with newer targeted drugs which are designed to target the specific treatment zone in the body. This verification can thus affirm that the drug is delivered to the region intended.
  • the evaluation can be advantageously used to identify either, or both, of the presence of a favorable or unfavorable treatment time ( Block 134 ). For example, if conditions indicate the tumor is not receptive to the planned treatment, a change in the planned therapy can be promptly instituted, or, in the reverse, the resistance can result in a rescheduling of a planned therapy to a more favorable time, thereby minimizing exposing the subject to unnecessary therapy sessions at unfavorable times.
  • the therapeutic evaluation can be based on either or both of relative or absolute parameter values (or indeed a clustering of irregular, positive, or negative parameter values) to determine if the treatment is progressing according to a predictive model.
  • the predictive model can be based on the deviation of the tumor's response to the delivered therapy at a particular point in time as measured against a population norm or even against a historical perspective of the patient's own responses to previously delivered therapies. This can allow a physician to choose (or modify) the therapy for a subject based on the responsiveness of the tumor itself.
  • the information can result in modification of the planned treatment regime ( Block 136 ). For example, for discussion purposes, assume that at Day 3 from a chemotherapy type and dose, the tumor oxygenation is low, and the normal cell's susceptibility to toxic agents is high. In contrast, assume that at Day 3, the tumor oxygenation is high, and the normal cell's susceptibility to toxic agents is low.
  • this behavior may be according to a predicted outcome or an unpredicted outcome; if unpredicted, one might proceed to schedule take advantage of the favorable conditions for treatment and schedule an additional therapy session promptly ( i.e ., a favorable active treatment time). If predicted, then the planned therapy can proceed as scheduled.
  • the electrode-measured pH of tumors is on average 0.4 units lower than normal subcutaneous or muscle tissue. Although overlap between normal and tumor tissue may exist, they may be explained by technical and patient-related factors. However, the present invention recognizes that measuring pH in both normal and tumor tissue at the same time and on a continuous basis can eliminate this variation. The ability to accomplish this can enable the physician to exploit the differences. Since the acidity increases with increasing distance from the supplying vessel and pH ⁇ is similar in each tissue, the intra to extra cellular pH gradient may be expected to increase in those cells most distal from blood vessels. The overall effect would be to enhance drug uptake and killing of cells that are normally exposed to the lowest drug concentration and especially relevant to radiation therapy in which low oxygen concentration -- and therefore radiation resistance -- increases with increased distance.
  • the sensor unit 50 (whether self-powered and implantable or injectable with an inductive powered version as will be discussed further below) can be inserted into the tumor(s) and secured therein or thereto in order to gather information, preferably for a number of weeks as discussed above.
  • the sensor elements 51 are configured such that they are placed at different levels and in different locations in the tumor. It is also preferred, as is also shown in Figure 19B , that at least one sensor element be configured to monitor the treatment toxic affect or normal cells and/or the pH level of the normal cell tissue proximate the tumor.
  • the tumor can be heated (hyperthermia) which works best in hypoxic conditions and which may eliminate enough cells to make the remaining population less hypoxic, or the tumor can be exposed to specific drugs to improve the oxygen concentration.
  • hypothermia which works best in hypoxic conditions and which may eliminate enough cells to make the remaining population less hypoxic, or the tumor can be exposed to specific drugs to improve the oxygen concentration.
  • the important point is that the tumor is not treated until more cells are oxygenated and, therefore, more sensitive or vulnerable to the conventional active treatments of radiation or chemotherapy.
  • the sensitivity and, therefore, cell kill of malignant cells can be affected by pH and cell proliferation. pH measurements of the tumor tissue would be important as the pH can influence not only the delivery and uptake of drugs, but also affect the oxygenation of the tumor.
  • the drug should be withheld and the pH changed.
  • Cell proliferation can be measured with the aid of a beta radiation sensor able to monitor uptake of any radioactive tagged substance or ligands and provide information on cell kinetics and proliferation. If the uptake of a particular ligand which measures for cell proliferation is high (indicating active cell proliferation and therefore increased sensitivity), then the drug or radiation should be delivered.
  • the present invention will now allow data to be collected on specific values of for each monitored parameter or variable (preferably including pH, oxygen tension, and cell proliferation) during and following cytotoxic treatment.
  • the collected data can be studied and a specific set of variables identified to affect a particular response. Armed with this information, a patient can be more effectively treated.
  • the present invention will now allow not only the establishment of specific variable information for evaluation, but, can also be used to direct and monitor the effects of treatment
  • the present invention configures a tumor monitoring system with sensor elements designed to monitor one or more of tumor pH, oxygenation level, temperature, and cell proliferation.
  • the cell proliferation can be measured presently by the use of a radiation sensor (which can also be used to verify the dose of radiation received at the tumor during radiation therapy). It is anticipated that other biochemical or biomolecules will be determined to be sensitive indicators of the vulnerability of the tumor for treatment and, thus, useful according to the present invention.
  • the present invention can provide all these sensors in each tumor, gathering and transmitting the information in real time, to a computer containing an algorithm to process the information to determine if and how the patient is to be treated.
  • the desirable values of selected physiological parameters are identified or defined as they relate to the desired condition proximate to an active therapy ( Block 200 ).
  • the desirable values for each of the parameters may be input as a minima or maxima and may be cross-related to a particular treatment type. That is, one parameter, for discussion identified as parameter " C" (such as pH), may require or desire a certain minimum or maximum value to achieve maximum effectiveness particular to a certain treatment type (such as a particular chemotherapy or drug treatment).
  • parameter "A" such as oxygenation level
  • parameter"A such as oxygenation level
  • oxygenation level may have the same preferred value across all treatment regimes (typically a minimum value as a normal or an elevated oxygenation level is desirable).
  • a minimum or maximum value at which therapy should not proceed it is identified as a test criteria for data analysis just prior to the delivery into the subject of the treatment.
  • a range of physiological parameter values particular to the parameter can be used as a basis for test criteria; for example, defining the levels associated with "elevated,” “decreased” and “normal” can be input ( Block 210 ).
  • This criteria (as well as relative levels, population norms, or other indices of tumor behavior and treatment efficacy) can then be used to define test conditions corresponding to evaluation of tumor treatments (Block 220 ). That is, the test conditions can be any number of tests representing evaluation of the tumor and the treatment. As shown, the test conditions also test for abnormal values of the monitored parameters ( Block 231 ). This can identify the malfunction of a sensor, sensor element, or other component of the monitoring system as well as identify a potentially immediate need for medical evaluation.
  • test conditions can include testing for elevated or decreased parameter values ( Blocks 232, 233 ) respectively.
  • the presence of a clustering of "favorable conditions" represented by two of the parameters having increased or elevated parameter values and another having a decreased parameter value ( Block 235 ) may represent a more favorable treatment period.
  • the presence of an elevated oxygenation level together with a period of increased cell proliferation and a decreased pH level may trigger a favorable treatment window.
  • the clustering of just the two increased parameters can also be a test condition.
  • one test condition can review the parameter values to determine variation from an expected value based on a predictive model (statistically relevant variation from a relative reaction or from a population norm) based on a point in time during or after active treatment ( Block 234 ).
  • a test condition which identifies whether the parameters meet the defined desirable values may also be helpful ( Block 236 ). It may also be beneficial to have a test to determine if an expected data monitoring (local and/or remote) has been received or is missing ( Block 237 ). This could indicate data corruption, file corruption, or even be used to automatically call the subject (such as with a programmed or recorded telephonic message) to notify them that a data transmission is needed.
  • the physiological data is periodically monitored ( Block 240 ) and the data is compared to the test conditions/defined values ( Block 250 ).
  • An unfavorable active treatment time and a favorable active treatment time can then be identified ( Blocks 260, 261 ), respectively.
  • the favorable test time can be identified by the test conditions/parameter values indicating a positive indicator (favorable condition or good progression).
  • the data may also reflect a norm indicator (neutral condition), and a negative indicator (unfavorable condition or resistance to therapy). It is envisioned that a global network database or a regional database associated with each hospital or clinical site identifying the appropriate values can be pre-established to minimize the data input needed for a particular subject.
  • each block of the block diagrams (or block in the flowchart illustrations), and combinations of blocks in the flowchart illustrations or blocks in block diagram figures), can be implemented by computer program instructions.
  • These computer program instructions may be loaded onto a computer or other programmable data processing apparatus to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create means for implementing the functions specified in the flowchart block or blocks.
  • These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart block or blocks.
  • the computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks and/or block diagrams.
  • blocks of the block diagrams or in a flowchart illustration support combinations of means for performing the specified functions and program instruction means for performing the specified functions. It will also be understood that each block of the block diagram or flowchart illustrations, and combinations of blocks in the block diagrams or flowchart illustrations, can be implemented by special purpose hardware-based computer systems which perform the specified functions or steps, or combinations of special purpose hardware and computer instructions.
  • the present invention will likely provide additional basis for establishing more definitive numbers or values for monitored tumor physiological parameters, the following parameters and levels and indicators are provided as suitable for establishing test criteria associated with treatment or tumor condition.
  • Conventional treatments use combination therapies such as temperature and radiation (tumor heated twice a week while irradiating every day).
  • the tumor is irradiated daily and heated twice per week following the daily radiation treatment.
  • the temperature range preferred to achieve an increased, and hopefully maximum, cell kill is between about 42-43.5 °C.
  • This temperature is then preferably maintained for about 20 minutes.
  • the temperature is monitored closely to minimize the effects on the surrounding normal tissues and to assure that the same temperature is substantially homogeneously obtained throughout the tumor.
  • This treatment technique is utilized and found to be effective for primary tumors from a number of tumor sites, including, but not limited to, the lungs, the prostate, the breasts, melanoma, the pancreas, and the pelvis.
  • the present invention can provide an easy and effective thermal monitoring means by which temperature can be monitored, the thermal monitoring can prove especially suitable for externally inaccessible tumors or for tumors located deep within the body, which are not easily monitored by conventional means.
  • normal can be described as levels from about 50-52mm Hg. While the term “decreased” can be described as levels at or below 49 mm Hg, and more preferably, below about 40 mm Hg. It should be noted that oxygen is important for most, if not all tumor types, and is not specific to one type of tumor (although a particular level may be more suitable for treatment of one type). Further, in situ sensors according to the present invention can be positioned at different positions within the tumor to monitor the distribution of oxygen. If a significant difference (or delta) is detected, an attempt can be made to increase the oxygen levels to a sufficient level across the tumor.
  • the radiation or chemotherapy treatment can be withheld and given only when the oxygenation level approaches a minimum of about 50mmHg or is within a range determined to be appropriate for that patient (based on a relative response and/ or absolute response data).
  • cell proliferation is an important property of malignant tumors which can effect outcome.
  • a knowledge of the time during which the tumor cells are proliferating is important in order to achieve a greater cell kill, and in turn, a greater response to therapy and an improved outcome.
  • the degree of cell proliferation is related to the number of cells, which are cycling. Thus, if a ligand associated with cell proliferation is tagged, it will be incorporated into cycling cells and reveal itself as increased radioactivity within the tumor. Under normal or quiescent conditions, only about 2-5% of cells are typically cycling. This quantity will increase generally by an order of magnitude to 20-25% in a moderate or highly proliferative state. The difference in uptake of the radioactive material will be noticeable and can be correlated to periods of increased cell proliferation.
  • the time during which this increased proliferation is not readily known and has not been readily identifiable. The time during which cell proliferation occurs may vary with the specific tumor type, as well as the rate of proliferation itself (the time it takes to double the population).
  • the pH of tumors has been found to be lower (more acidic) than the pH associated with normal tissue.
  • the precise pH or range of pH needed for maximum effect is not known, nor have the fluctuations encountered during treatment been quantified as noted above.
  • the impact of information regarding pH can be more complicated than that oxygen since pH may effect oxygen level, drug uptake, and cell proliferation.
  • surrounding normal tissue can also effect the tumor pH.
  • a more acidic environment pH of between about 6.8-7.0
  • a more acidic environment may be preferably for treating malignancies. This is based on in vitro data which indicates that at least one drug, adriamycin, is more effective at low pH.
  • the difference in pH between normal and malignant cells can be narrow (about 0.4 units) and therefore may indicate that there is a narrow treatment range at which drugs and radiation are more effective.
  • the present invention can now determine, in real time, the changes that occur during and after cytotoxic therapy.
  • Radiation monitoring can be used to identify cell proliferation above (typically beta radiation). Radiation sensors can also be used to verify irradiation doses delivered during photon irradiation treatment (typically in the range of between about 3000-6000 cG). Thus, use of a radiation monitor during real time delivery can help control a more precise delivery dose of gamma radiation to the tumor site (distribution of dose within the tumor following photon irradiation or verification of calculated dose, especially with high dose conformal therapy). ⁇ radiation monitors can also monitor radioactively labeled compounds to monitor drug uptake and utilization, blood flow the tumor, sensitivity to specific drugs, drug distribution in various organs (as well as cell proliferation discussed above).
  • a number of tumor (and proximate normal cell) parameters can be monitored, each of which can provide information material to the treatment and condition of a tumor in a subject.
  • Individual parameter combinations thereof, and biomolecular tumor parameters yet to be identified may also be monitored according to the present invention.
  • Implantable glucose sensors have been constructed using polyethylene cases covered in Dacron velour, with the sensor surfaces being coated with a variety of bioprotective membranes (Gilligan et al., 1994). (These units were wet sterilized in 0.05% thimerosal for 24 hours before being implanted and tested in vivo for up to three months.) A more common method used for sterilizing implant devices is gas sterilization at temperatures of 115° C to 120° C for 20 minutes.
  • Integrated circuit (IC) technology has been used significantly for biotelemetry device electronics throughout the past two decades. In the mid 1970s, IC usage was made feasible through the use of hybrid technology. This technology enabled engineers to construct telemetry devices by interconnecting commercially available ICs, simple custom ICs, and other discrete components, on ceramic substrates through the used of thick- or thin- film technologies (Fryer et al., 1973; Deutsch, 1979; Gschwend et al., 1979; Donald et al., 1981). Perhaps the best example of this technology is a unit perfected at NASA Ames (Hines et al., 1995). NASA uses a carrier of 455 kHz and digital PCM.
  • the implanted unit is fabricated using hybrid technology and monitors pH, heart rate, temperature, and battery voltage. Its current consumption is less than 120 microamps drawn from a 0.75 A-hr lithium battery. The battery lifetime is 6 - 9 months.
  • the unit is packaged in a custom-manufactured, disk-shaped ceramic package, approximately 3.0 cm in diameter occupying a volume of 20 cc.
  • the telemetry link has an acquisition range 12 to 24 inches.
  • telemetry units could be fabricated on individual silicon substrates only millimeters in length and width.
  • biotelemetry systems have been appearing with custom integrated circuits as a major component (Oshima et al., 1987; Williams et al., 1994; Wouters et al., 1994; Akin et al., 1995).
  • an intelligent 4-channel unit was designed and fabricated for animal husbandry studies. The electronics used for this device were created on a 4.7 x 7.1 mm 2 silicon substrate and included both analog and digital signal conditioning electronics to process the incoming signals, transmit them accordingly, and direct power to the appropriate subcircuits when needed.
  • a novel implantable telemetry system was recently under development at North Carolina State University (Fernald et al., 1991 and 1992).
  • the system was intended for rapid-prototyping applications, and was designed such that a non-engineering researcher could construct a customized implant device with minimal effort.
  • the system consisted of two core intelligent integrated circuits, a microprocessor/telemetry chip and a data acquisition chip that could be stacked upon one another and fully interconnected with less than ten bus wires. Although the data acquisition chip provided eight input channels, additional channels could be attained by stacking additional such chips and attaching them to the bus lines in a daisy-chain manner.
  • the microprocessor was fully programmable (both before and after implantation) and possessed an instruction set suitable for processing biological signals.
  • the system was intended for a variety of transducers with varying bandwidths. As a consequence of the serial bus architecture, the system throughput was limited to an aggregate bandwidth of 20 kHz, suitable for most applications.
  • a second example system incorporating inductive powering was designed for orthopedic measurements (Graichen et al., 1991 and 1995).
  • This unit implemented eight telemetry channels (6 for strain sensing, one for temperature, and one for power supply voltage).
  • the electronics module was a thick-film hybrid substrate with custom IC and discrete components.
  • the substrate was encapsulated in a titanium cylinder measuring 8 mm in diameter and 27 mm high.
  • the telemetry links operates using pulse-interval modulation with a carrier frequency of 150 MHz. The operating range is 20 cm.
  • the implant is inductively powered through a 4 kHz coupling channel.
  • Inductive powering is also finding applications in cardiovascular and neural studies.
  • a novel 3D power steering scheme has been proposed for high-data rate cardiac mapping studies (Mueller et al., 1995).
  • researchers have also implemented inductive powering in some telemetry-controlled neural stimulators. Their size has been greatly reduced, allowing them to be injected into tissue through a hypodermic needle.
  • Two such devices have been reported by researchers at the University of Michigan (Akin et al., 1990) and the Illinois Institute of Technology (Loeb et al., 1991). Both systems rely on micro coils and magnetic induction to power the devices, thus eliminating the size and weight associated with batteries.
  • the inductive links were also modulated to convey command information to the implants. Further reduction in size was achieved through CMOS integrated circuit technology.
  • Both research groups proposed incorporating reverse communication capabilities, so that the implanted devices can also perform telemetry monitoring functions (Nardin et al., 1995).
  • Telemetry units from Mini Mitter are very small in size (XM-FH series - 9.0 mm (dia.) x 15 mm; VM-FH series - 12 mm (dia.) x 19 mm). They use the pulse interval modulation transmission mode to achieve very low power operation. However, they monitor only a single channel. Therefore, stacking several single channel transmitters to build a multi-channel device could make the combined size unacceptable. Small button-type batteries are used and are easy to replace. These units are attractive for single channel applications.
  • Biotelemetrics (Boca Raton, Florida) builds transmitters whose carrier frequency is adjustable, which makes it possible to stack a series of single channel transmitters to make a multi-channel unit.
  • the size of a typical unit is approximately 2.5 mm x 7.5 mm x 10 mm.
  • the transmitters can be turned on and off periodically to reduce the power consumption.
  • the electronics exhibits a high input impedance which enables the unit to be connected to any kind of sensor (e.g ., thermistors, pH sensors, and other ion-selective sensors).
  • Konigsberg Instruments offers four- and eight-channel implants for measuring temperature and biopotential signals (such as EEG, ECG, and EMG) with a bandwidth up to 1 kHz.
  • the units range in size from the smallest 1.0 cm x 1.5 cm x 3.3 cm to the largest 5.1 cm x 2.3 cm x 1.5 cm.
  • the units are battery powered and the battery life ranges from five to 20 months.
  • An RF switch is included to turn the battery on and off.
  • the transmit range is typically 3 - 5 m.
  • Multichannel amplifier units are also available to receive the transmissions from the implants and relay them to a remote base station.
  • Button battery cells have been available for nearly three decades, and were extensively used in hearing-aid devices.
  • the most commonly used cells of this type are available in two chemistries - zinc-mercury oxide and zinc-silver oxide.
  • the primary functional differences between the two are as follows: (1) zinc-mercury oxide exhibits a flatter discharge voltage characteristic over time, (2) zinc-mercury oxide responds better to momentary high-power demands (low internal resistance), (3) zinc-silver oxide has a higher output voltage, specifically 1.5 to 1.6 V, versus 1.35 V from zinc-mercury oxide, and (4) the volumetric energy density of zinc-silver (monovalent) is greater ranging 400-550 Wh/cm 3 .
  • the service capacity of these cells is typically near 100 mA-hours.
  • lithium-anode based cells Another alternative to these cell types are the recent lithium-anode based cells. These cells are desirable because their output voltages (near the 3 volts needed for ICs) are typically twice that of zinc-anode cells. Another notable difference is that lithium cells are typically available in flat packages and are appropriately termed "coin-cells.” From a volumetric standpoint, the energy densities of most lithium-based cells compare favorably to zinc-based cells. For example, lithium-iodine cells exhibit a 2.8 V output with a high energy density of approximately 1,000 Wh/cm 3 . Pacemakers have used lithium cells since the 1970s.
  • the in situ sensor units 50 of the present invention are configured to be one of implantable or injectable into the subject.
  • Figures 5 , 6 , 21 , and 22 illustrate preferred implantable embodiments
  • Figure 8 illustrates an injectable embodiment.
  • Figure 9 illustrates a hybrid sensor unit 50" having both an implantable satellite sensor body 50S and associated injectable dependent sensor bodies 50D.
  • Each of the sensor units of the present invention are powered either by a battery ( Figure 5 ), or, and more preferably, is inductively powered ( Figures 6A , 8, and 9 ).
  • Each of the (implantable or injectable) sensor unit bodies is hermetically sealed with biocompatible materials and sterilized by methods well known to those of skill in the art.
  • the sensor unit 50' is configured with at least one sensor element 51 .
  • the sensor element 51 shown in Figure 5 is a thermistor. More preferably, as shown in Figure 6a , the sensor unit 50 comprises a plurality of sensor elements 51a-51e , which are preferably configured to monitor one or more of temperature, radiation, oxygen, and pH. Suitable discrete pH, radiation, and temperature elements 51a-51e are known to those of skill in the art.
  • the preferred temperature sensor type is a thermistors.
  • the preferred radiation sensors are well known such as MOSFET (metal oxide semiconductor field effect transistor) based designs. Preferred self-calibrating oxygen and combination oxygen/pH sensor embodiments will be discussed further below.
  • the temperature sensor element for the present invention is configured to operate in the temperature range of about 35° C to 45° C with an accuracy of about 0.1 °C. Size is of major importance since the entire implantable device should be minimally invasive. Preferably, the entire implantable sensor unit is sized to be less than about 1.0 cm 3 . Further, the sensor units 50 , 50' , 50" of the tumor monitoring system 10 are configured to operate even when exposed to a radiation field That is, the sensor unit 50 , 50' , 50" do not necessarily have to function while the radiation is being administered to the tumor, but they preferably function immediately afterward. The sensor unit 50 , 50' , 50" is thus configured to respond quickly (within a few seconds) after radiation administration. In a preferred embodiment, as shown in Figure 8 , the sensor unit 50" is sized and configured such that it can be placed on the tip of an insertion probe and injected via a large bore canula such as via image guide placement into position.
  • the sensor unit 50 is configured with a primary body portion 50B and a plurality of arm portions 50A extending outwardly therefrom.
  • the arms 50A have a thin planar profile.
  • the arms 50A are formed of a flexible biocompatible substrate material such as a polyimide (like Kapton ® , a polyimide material).
  • At least one sensor element 51 is positioned on each arm 50A , preferably at a distal portion (away from the primary body 50B ).
  • a separate channel 151 electrically connects the sensor element 51 to the electronic operating circuitry 125 positioned on the primary body 50B .
  • each channel is defined by a pair of leads (the sensor O 2 may have greater than two (2) leads) formed by metal vapor deposition onto the top surface of the flexible substrate.
  • the transmitter coil 58 is substantially circumferentially layered to surround the electronics 125.
  • the electronic circuitry 125 includes at least one, and preferably a plurality, of fixed resistors 125R for signal data reference as will be discussed further below.
  • a biocompatible coating 160 is applied (to preferably encasulate, and more preferably, hermetically seal) to the exterior of the sensor unit 50 .
  • Surface mounted electrical components can also be located on the bottom surface of primary body 50B , with interconnection being made by plated through vias (a common method used in flexible printed circuit board technology).
  • this multi-arm configuration can provide increased regional data to allow for more informal analysis of the tumor.
  • the multiple sensor elements 51 can contact different locations within (penetrate at different depths) and/or wrap to contact different exterior perimeter locations along the tumor.
  • one or more arms can be attached to normal tissue to provide information regarding the status of same.
  • the sensor arms 50A are preferably configured with attachment means 150 to secure their position in the subject.
  • sensor element 51A illustrates an aperture 150 formed in a distal position of the substrate to allow a suture to attach it in position.
  • sensor element 51b illustrates a barbed outer surface 150' .
  • Figures 7 , 8A , and 8B illustrate a sensor unit 50" which is cylindrically shaped and sized for injection, e.g ., an injectable sensor unit 50I .
  • a PCB or IC chip 125p is oriented to extend a small distance along a length of the sensor body.
  • the coil 58 also cylindrically extends to surround a portion of the PCB or IC 125 .
  • the PCB is a substrate (preferably a flexible substrate) which extends a distance outside the coil 58 (for an overall length which is less than about 0.5 inches).
  • this size can be further reduced.
  • the IC or PCB can be configured and sized to extend substantially the same distance as the coil 58 .
  • the sensor body can be configured to hold a single channel (i.e. , one sensor element for a PCB version having a width of about 3mm) or multi-channel (multiple elements, with each channel layed side by side, and typically wider than the single channel version).
  • the tip 125T of the sensor unit 50I can be configured with a rounded or pointed edge to help facilitate entry into the tumor tissue.
  • the entire sensor body is encapsulated with a biocompatible material and sterilized for medical applications.
  • both the injectable and implantable versions 50I, 50 , respectively, of the sensor units of the present invention are inductively powered. That is, the monitoring system is configured to act as a transformer (with one coil on the surface of the patient's body and the second within the monitor) to couple and power the internally disposed sensors, as is well known to those of skill in the art and discussed briefly above.
  • the in situ sensor units 50 , 50' , 50" , 50"' are self-contained, and have a sufficiently long service life in the body to provide clinically useful chronic information for episodic or chronic treatment decisions, and can be miniaturized without requiring catheters or externally connected wire leads into the sensors and out of the body.
  • the coil 58 can be integrated into the circuit board itself via a ferrite substrate (a flux concentrator). Further, the circuit board 125p and its associated electrical components can be configured as a miniaturized chip which allows the coil 58 to be similarly miniaturized. Note, however, that the signal is typically proportional to the area of the coil and, as the area of the device decreases, the signal strength associated with the coil 58 on or around the device can decrease.
  • the temperature sensor resonant element can be configured as a positive temperature coefficient (PTC) (typically ceramic).
  • PTC positive temperature coefficient
  • NTC negative temperature coefficient
  • FIG 9 illustrates a hybrid sensor unit 50''' version of the inductively powered implantable and injectable sensor units 50 , 50I described above which allows for miniaturized sensor element bodies and useful signal strength at transmission.
  • this sensor unit 50"' embodiment includes a satellite sensor unit 50S with the IC or externally communicating electronics 125 thereon and a plurality of dependent sensor units 50D.
  • the dependent sensor units 50D are inductively coupled to the satellite sensor unit 50S which is, in turn, inductively powered and coupled to the external system. Further, the dependent sensor units 50D are telemetrically connected 60I to the satellite sensor units 50I , which is telemetrically connected 60 to the external receiver 75 .
  • each dependent sensor units 50D 1 can be electronically encoded or identified or positionally related to a particular channel or port within the satellite sensor unit 50S to maintain relative (if not absolute) positional information for consistent data analysis of the transmitted sensor data for the monitoring system 10 .
  • Figure 19A illustrates another embodiment of the present invention, at least one wherein the tumor monitoring system 10'" employs a plurality of sensor units 50 . That is, at least one sensor unit 50 is positioned at a different (separate) tumor site as shown.
  • This multi-sensor unit tumor system 10"' can result in more regional specific information to adjust treatment as necessary to effective in each tumor site of concern.
  • the multi-sensor monitoring system 10"' will configure each separate sensor unit 50 , 50" , 50"' to be electronically identifiable to maintain data integrity and correlation to the tumor site/particular location.
  • the receiver 75 should be positioned proximate to the sensor unit coil 58 (typically about 30 cm) for proper data transmission, it is preferred that the receiver 75 be configured to move to overlay the appropriate sensor unit during transmission (indicated by the arrow and dotted line movement of the receiver in Figure 19A ) and it is also preferred that the receiver 75 be programmed to recognize the order of sensor unit transmission to assure data integrity.
  • two receivers can be used, one for each sensor unit location. This may be especially appropriate for non-clinical use, such as at a patient's home wherein a patient interactive system may be needed.
  • a dual receiver configuration whereby a user can keep in position a portable receiver over each monitored tumor site, can be advantageous.
  • an external mark or indices of alignment to allow proper alignment may also be helpful (both in a single tumor/region sensor unit embodiment and a multi-sensor unit/spaced position embodiment).
  • This can be a semi-permanent physical mark 175 made on the skin and/or other infrared or photogrammetric position readable or indication means which can cooperate with the receiver 75 (receiver loop) such that the receiver 75 can send out a position verification beam to facilitate proper alignment before/during transmission at the selected location.
  • the tumor monitoring systems of the instant invention are preferably configured to transmit information at a low or very low bandwidth. That is, the carrier bandwidth is preferably in the MHz range while the modulation frequency is more preferably at or below about 1kHz.
  • This low bandwidth operation allows transmission of signal data received from the sensors across slow communication links such as modem and voice telephone connections.
  • the measured signal information is encoded into one of several time-based modulation schemes. The time-based encoding permits accurate data transmission across communication links that may convey amplitude information inaccurately and frequency information accurately, such as the voice telephone network.
  • the monitoring equipment is preferably small and relatively inexpensive or cost-effective to be set-up and operated at remote locations.
  • the low bandwidth operation is not required as the data from the sensor units 50 , 50I , 50S can be converted into essentially any number of suitable encoding or transmission schemes that are suitable for remote operations, as discussed above, such as substantially continuous or semi-continuous monitoring with a PC at the remote location and storing the data associated with same with time/date stamps so that a complete data set or data segment/record covering a period of hours, days, weeks, or longer can be gathered and transmitted to the central processing site over one or more discrete relatively short data transmitting sessions.
  • the thermistor is by far the most sensitive. It has a fast response time and a high output for interfacing, and small devices are commercially available. The non-linear response is not critical over the small temperature range in which the sensor will function (typically less than about 10°). Although the interfacing circuits require a current source, the silicon overhead is only a few additional transistors. The device is considered fragile for industrial purposes, but should be amply rugged for this application. Sensor self-heating is reduced since the device operates in a limited temperature range and the current can be small and need not be applied continuously. If a battery source is used, the sensor element is preferably insulated or positioned spatially away to reduce its exposure to heat attributed to the battery.
  • a single-channel, discrete-component, commercial telemetry unit was purchased (Mini Mitter, Inc., Model VM-FH) with externally mounted thermistor.
  • Figure 2A illustrates the principle of operation of a hyperperthermia treatment with a Thermotron® device. An eight MHz RF signal is applied between the plates of the machine which causes ions between them to oscillate.
  • the agar-gel phantom is approximately the size of a human torso and mimics the heating characteristics of body tissue.
  • the skin surface temperature is always monitored.
  • catheters are normally inserted through the skin surface into the tumor undergoing treatment and its vicinity.
  • thermocouple probes are inserted through these catheters to record tumor temperatures as the RF energy is applied.
  • This experiment was designed for two purposes. First, the performance of the insulated thermistor was compared to that of a Thermotron® thermocouple, and secondly, to observe the heating effects of the Thermotron® device's RF energy on a bare, button-sized battery placed in the agar-gel.
  • the experimental setup is illustrated in Figure 11 .
  • Two catheters 99 were inserted into the agar-gel phantom 101: one positioned near the thermistor 99R and the second near the battery 99B .
  • Thermotron® device thermocouple probes were inserted into the catheters and RF energy was applied to the agar-phantom to gradually sweep its temperature over the therapeutic range.
  • the experiment was designed to be conducted over a 75-minute time period to ensure that the agar gel was heated uniformly.
  • the results of the experiment are presented in Table 1.
  • the first two columns of Table 1 show the time progression of the experiment and the temperature reading from the Thermotron® device's instrument panel taken from thermocouple-1 (see Figure 11 ). This measurement was assumed to be correct and was used as the reference or " gold" standard.
  • the third column shows the relative change in the temperature of thermocouple-1 from its initial value in the first row.
  • the fourth row shows the relative change in the thermistor's readings at the same measurement times. Note the close correlation with the Thermotron® device's thermocouple readings.
  • thermocouple-2 located near a button-sized battery placed in the agar-gel phantom.
  • the temperature near the battery increased to a larger extent as the RF energy of the Thermotron® device heated the agar-gel over the therapeutic range.
  • thermocouple-1 near the thermistor increased by 8.8°C
  • thermocouple-2 near the battery increased by 11.1°C. This indicates that any implant that is powered by a battery should be properly thermally insulated to minimize its impact on temperature sensors that are monitoring the environment of tumor cell populations.
  • the next task was devoted to designing and building a 4-channel, discrete-component prototype circuit using breadboarding techniques.
  • This circuit utilized four thermistors for temperature monitoring.
  • a block diagram of the circuit is illustrated in Figure 12 . Temperature increases were sensed by the four thermistors 51a-51d in response to a corresponding reduction in resistance.
  • a constant current source driving the thermistors 51a-51d was used to measure the resistance.
  • the amplifier 53 voltage output was proportional to the resistance change.
  • a voltage to current converter 54 attached to the amplifier 53 was used to charge a timing capacitor 56 .
  • the time period for the voltage on the timing capacitor to reach a threshold was proportional to the change in resistance in the thermistor 51e , and hence proportional to the temperature change at the thermistor's surface.
  • Figures 13 and 14A -14C show suitable operational design for sensor circuits.
  • the transmitter 157 sends a signal burst at 1.0 MHz to the coil 58 .
  • the threshold detection circuit 158 discharges the capacitor 56.
  • the capacitor 56 is allowed to again begin charging toward the threshold value. If the amplifier 53 voltage is high, a large current is dumped into the capacitor 56 leading to a short charging time interval. If the voltage on the amplifier output is zero, then no current is dumped into the timing capacitor 56. In this case, a small current source was included to ensure that the device is operating properly. This small current source forced the transmitter 157 to send out signal bursts at a large time interval for testing purposes. Longer time intervals indicate lower temperature measurements, while shorter ones indicate higher temperatures.
  • the clock, counter, and control logic 155 , 156 serve to multiplex the four thermistors 51a-d over the biotelemetry channel in a round-robin fashion.
  • a modified AM radio receiver attached to a laptop PC running LabVIEW ® software (National Instruments, Inc., Austin, TX) was used to detect the transmitter bursts. Water bath experiments were used to validate the operation of the implant design. The range of the telemetry link was about 30 cm.
  • a surface-mount (SMT) unit was designed and constructed to reduce the size.
  • the circuit of Figure 12 was refined and a double-sided, 2.5 x 3.5 inch, printed-circuit (PCB) was fabricated. Low profile SMT components were used. The power consumed was 4.5 W from a 3.0 V battery.
  • the transmitting coil 58 (13.5 mm in diameter) was formed with 25 turns of #38 AWG copper wire, producing a range of 30 cm.
  • Four thermistors 51a-d were attached to the device and the water bath experiments were repeated. Results were similar to the earlier experiments verifying the functionality of the system.
  • IC test chip was designed. Its purpose was to demonstrate that the operating concepts adopted for the SMT unit can be adapted for integrated -circuit technology.
  • Figures 15 and 16 depict the functional blocks of the IC design and its chip layout.
  • the circuit design was first refined and simulated using SPICE. Then an IC layout was performed using standard cell technology. The circuit was specifically designed to minimize its susceptibility to latch-up.
  • the test chip was implemented using the MOSIS fabrication service (2.0 micron, CMOS, n-well, low-noise, Orbit analog process, tiny-chip frame).
  • MOSIS fabrication service 2.0 micron, CMOS, n-well, low-noise, Orbit analog process, tiny-chip frame.
  • Several internal test points were inserted to allow complete testing of the IC subcircuits.
  • Four ICs delivered in dual-in-line (DIP) packages were mounted in an IC prototype unit constructed using a small PCB (1.5 x 4.0 cm). All four ICs were subjected to benchtop
  • the test chips were exposed to a series of radiation and thermal tests.
  • First the units were thermally tested using a temperature-controlled water bath as shown in Figures 17A and 17B .
  • the IC prototype unit used seven channels for sensor data. Four of the channels were connected to thermistors and the remaining three were connected to fixed resistors.
  • Figure 17A illustrates that the thermistors caused the channel pulse width to vary by approximately 0.03 ms per 0.1°C while, as shown in Figure 17B , the fixed resistor channels varied by about 0.003 ms per 0.1° C.
  • thermistor and fixed resistor data in Figures 18A and 18B suggest that the increase in pulse width during exposure to radiation is due to changes in the active transistor parameters of the IC. These parameter changes are expected based on the experience of many researchers in the effects of radiation upon microelectronic circuits (NPS, 1997). Therefore, the IC device can be considered as a sensor for the radiation exposure.
  • a fixed resistor channel can be used to measure total exposure. From calibration data for each implant during manufacture, the initial pulse width for the fixed resistor channel will be known. From statistical data obtained about the behavior of the ICs under radiation exposure (data similar to Figures 17A and 17B ) , the slope of the curve will be known. Therefore, real-time measurements from the fixed resistor channel can be compensated to account for the variation based on the reference fixed resistor and known calibration data to give an accurate indication of the radiation exposure history for the implant. Using this total exposure computation, the temperature reading from the thermistors channels can be corrected mathematically to give accurate temperature reading at any radiation exposure level. That is, radiation damage or exposure can cause IC drift, and temperature drift.
  • a known fixed resistor value which is constant
  • a temperature sensor value which varies only in response to temperature
  • the IC which is affected by both (thermal and radiation).
  • Use of the calibration data established at set-up (or in the factory) can calibrate the signal data based on the number of known parameters to determine the radiation based drift and adjust for same. This drift is correctable as the dose of radiation is well within the drift adjustment as indicated by the Figures 17 and 18 .
  • a computer means can computationally perform the correction based on the data it receives from one or more fixed resistors.
  • At least one fixed resistor 125R be used in the operating circuitry of the sensor, and preferably a plurality of fixed resistors.
  • Figure 14B illustrates one fixed resistor channel (one reference) and four active monitoring channels.
  • the sensor unit 50 includes three resistors, one is substantially invariant with temperature or radiation (the fixed resistor 125R ), one changes with temperature (a thermistor), and one changes with both temperature and radiation (typically the MOSFET's in the chip have a resistance that changes with both).
  • the thermistor has an associated measured temperature dependent curve.
  • the fixed resistor can be used to correct the bias on the MOSFET" S (adjust or compensate for their drift due to radiation exposure/damage).
  • the computer can give a corrected reading such as a temperature profile.
  • the implant device may be powered down when radiation (high dose-rate gamma, thermal RF and microwave, or ultrasound) is applied to the patient.
  • a series of tests were conducted to determine the effects of exposure/energy challenge events from exemplary treatment sources at Triangle Radiation Oncology Services (TROS).
  • the tests were repeated for gamma radiation using a Varian Clinac 4/80.
  • the tests were again repeated using microwave (915 MHz) energy from a Clini Therm surface tumor heating instrument. In all cases, the device was not damaged by the energy challenge tests, and continued to make accurate temperature measurements after the conclusion of the tests. All test were conducted on the same implant device so that the cumulative effect of the challenge tests were negative.
  • the substrate 120 can be fabricated using five-mil flexible Kapton ® polyimide material covered by a 25 micron copper layer.
  • the metal layer 122 is patterned using photolithography into the wiring harness for a simple oscillator circuit.
  • an insulating layer of polyimide can be deposited and patterned to open conducting vias to the metal traces.
  • surface mount electrical components 125 are placed and soldered to the substrate.
  • a thermistor 51 is connected to the end branch of the implant substrate as shown in Figure 5 .
  • a coil of antenna wire 58 is mounted with the IC and/or SMT components 125 as illustrated in the figure.
  • a lithium coin-shaped battery 52 is attached to the substrate 120 .
  • the battery 52 is first affixed to the substrate in the position shown in Figure 5 .
  • the end flap 129 (the circle that contains the second battery connection) is then folded over the battery and attached using conducting silver epoxy.
  • the entire device is then encapsulated in a biocompatible material such as a thin layer of silastic and/or medical-grade silicone to protect it from the biological environment during implant.
  • sensor units 50, 50', 50", 50"' can also be included in sensor units 50, 50', 50", 50"' based upon the specification of the user interface.
  • the ability to turn the battery on and off with an externally applied RF signal can be included in an IC (chip) design.
  • Another feature can be the inclusion of pH sensor interface electronics.
  • the pH sensors will preferably be implemented on a biocompatible, flexible substrate such as the Kapton ® substrate shown in Figure 10A (Cosofret, 1995). This design is compatible with the Kapton ® substrate shown in Figure 5 .
  • the present invention employs self-calibrating oxygen, pH, or combination oxygen/pH sensors.
  • the operating principle of the in situ, in vivo self-calibrating chronically implanted sensor units 200 , 201 , 300 is based on water electrolysis at noble metal electrodes as shown in Figures 20 and 22 .
  • Oxygen or hydrogen can be evolved by the electrolysis of water by applying a current through a generating electrode (" GE" ) 227 and counter-generating electrode (“GE"') 227' for a certain period. Accumulation of these dissolved gas molecules at the GE 227 , in turn, rapidly establishes a microenvironment of oxygen saturation or hydrogen saturation in close proximity to the microsensor.
  • a two-point calibration procedure for the oxygen sensor unit 200 can then be performed, with the high point calibration being established in an oxygen-saturated phase, and the low point calibration in an oxygen-depleted phase that is produced by saturating the microenvironment with hydrogen. These transient perturbations of the microenvironment are expected to equilibrate rapidly with the surrounding medium (tissue). With this in situ, in vivo self-calibration sensor units 200 , 201 , 300 periodic sensor calibration can be performed to check the operability and biosurvivability of a chronically implanted device.
  • the self-calibrating sensor units 200, 201, 300 be configured with the following operational and physical specifications:
  • the water electrolysis method can be extended to perform a one point, in situ, in vivo calibration of an implanted pH sensor unit 201 ( Figure 10B ) as well.
  • a micro pH sensor unit 201 that is surrounded by a generating electrode will experience a titrating pH microenvironment during water electrolysis. If one repeatedly drives the electrolysis current forward and backward through the generating electrode, the highest slope in the time response of the pH sensor will occur at the moment of neutral pH (pH 7.0).
  • a one-point calibration at neutral pH can be performed during water electrolysis by checking the first derivative of sensor response during titration.
  • the functionality of similar pH titrating microdevices has been demonstrated for a pH-static enzyme sensor or buffer capacity sensor (Olthuis, 1992). This prior work strongly supports the feasibility of one point pH calibration as an option in tumor monitoring applications.
  • polarographic micro-oxygen sensors were fabricated on flexible Kapton ® material.
  • the basic electrochemical three-electrode cell configuration shown in Figure 21 was adopted to avoid current flow and minimize surface material consumption in a micro-reference electrode. All electrodes were designed to be geometrically symmetric to assure diffusional mass transport of electrochemical species in all radial directions.
  • Figure 21 is a photograph of the fabricated prototype oxygen sensor 200 (concentric configuration). All noble metal electrodes were made of gold, the material that has been shown to possess the best stability when used as an oxygen catalyzer (Hoare, 1984).
  • the middle electrode serves as a working electrode (" WE") 225 at which dissolved oxygen molecules are electrochemically reduced.
  • WE working electrode
  • the GE 227 is wrapped around the working electrode; this configuration will establish oxygen-saturated or hydrogen-saturated microenvironments during self-calibration cycles. Proceeding from inside to outside, the next concentric circle is used as the reference electrode (“RE") 229.
  • RE reference electrode
  • the outermost electrode in Figure 21 is the counter electrode ("CE”) 231 of this three-electrode cell. It is placed as far as possible from the WE 225 to eliminate electrochemical.interference at the WE of byproducts generated at the CE 231 .
  • the GE' 227' (not shown) is also located remotely from the WE 225 for this same reason.
  • FIG. 10A illustrates a pH sensor structure containing a p-HEMA central dome over a Ag/AgCl electrode.
  • the final fabrication step is the deposition of the outer polymeric membrane containing the pH ionophore.
  • These sensors have performed accurately in preliminary tests in vivo in blood for up to two months.
  • the size of these potentiometric sensors are preferably minimized to improve their capability for resolving spatial gradients. Further size reduction of the pH sensors shown in Figure 10A may be limited by the manual deposition of the polymeric membrane solution, weaker adhesion to the substrate and high impedance, as the membrane contact area is diminished.
  • O 2 sensors such as shown in Figure 21
  • BMMSL Biomedical Microsensors laboratory
  • Tables 2 and 3 summarize a preferred fabrication process of oxygen sensors 200 and pH sensors 201 , respectively.
  • Oxygen Sensor Process Process Steps Process Details Substrate selection 3-mil Kapton ® VN Cleaning Organic solvent cleaning and dehydration Metal Deposition US Magnetron sputtering 200 ⁇ Cr followed by 2000 ⁇ Au Photolithography Spin coated 1.3 ⁇ m Shipley 1813 photoresist,. Contact exposure with Tamarack Alignment and Exposure System.
  • FIG. 22 Another preferred embodiment of an in situ sensor unit is shown in Figure 22 as a combination pH/O 2 sensor unit 300 .
  • the combination sensor unit 300 assumes smaller feature sizes, the area of the generating electrode and, thus, its current carrying capacity, is reduced.
  • a smaller structure will also enable the new sensors to be employed in linear arrays for gradient measurements.
  • the microenvironment of the smaller sensor may require less oxygen to become saturated. Once the GE 327 has established a saturated microenvironment, these conditions will be dissipated rapidly unless structural measures are taken to delay oxygen and pH equilibration.
  • the self-calibrating design can employ a recessed structure (a micropool) to sustain the saturated microenvironment for a limited sensor calibration period.
  • a 3-dimensional micropool can be configured by using layers of photosensitive polymers to build walls to confine the working and generating electrodes 325 , 327 .
  • the volume of the micropool can also determine the overall sensor unit 300 performance and the time period needed for calibration.
  • a near optimum design can be determined by iterating several of the design parameters in various fabrication runs. It is noted that some surface degradation and adhesion problems at the polyimide/metal interface at the electrode edges were observed during prototype experiments (at current densities exceeding 10mA/cm 2 ).
  • the conventional Clark oxygen sensor contains a reference electrode (anode) and a working electrode (cathode) located in the same compartment encapsulated by hydrophobic, electrically non-conducting membrane.
  • the instant design separates the RE 329 and WE 325 to allow a space for the GE 227 (positioned therebetween and placed to control the micro environment of the WE 225) as illustrated in Figures 21 and 22 .
  • This new arrangement is in contrast to the conventional Clark sensor, which may not be suitable for long-term implantation due to the risk of membrane rupture and the subsequent degradation of the sensor's internal filling solution.
  • the separated RE and WE are electrically coupled via a hydrophilic permeable membrane and tissue fluids.
  • This separated configuration for the RE and WE can cause difficulties due to increased solution resistance when the anode is very far from the cathode.
  • the 3-electrode system reduces this effect.
  • Another difficulty can be introduced by WE surface contamination due to direct contact with components of tissue fluid that penetrate the permeable membrane.
  • the electrode material used be selected to reduce this behavior. For example, it has demonstrated (Holmstrom, 1998) that a bare gold electrode, implanted up to 4 years for oxygen monitoring, absorbed less blood proteins than a glassy carbon electrode, and no adverse tissue reactions were observed.
  • the operation of the sensor 300 is preferably divided into separate calibration and measurement modes.
  • the counter electrode (CE) will preferably serve a dual as the counter-generating electrode (GE') of generating source.
  • GE' counter-generating electrode
  • a silicon wafer-supported flexible substrate process is used to reduce thermal expansions and surface roughness distortions.
  • polyimide DuPont P12723
  • the wafer is soaked in a dilute H.F. solution. The thermal oxide is etched away and thereby releasing the flexible polyimide substrate and its sensor structures.
  • a recessed sensor structure can also be implemented using photosensitive polymer materials. Thicknesses of up to 30 ⁇ m can be obtained with a 2-step spin-coating procedure. Other materials are also available for this purpose. For example, a dry film (DuPont Pyralux or Vacrel which have thicknesses of 25 to 100 ⁇ m) can be laminated over the device using a thermal vacuum process. The highest aspect ratio (depth:width) for the micropool that can be fabricated using these laminated films is typically about 1:1. This ratio can be maintained for depths from 10 to 100 ⁇ m.
  • Platinum is known as the best noble metal electrode for water electrolysis and is easily deposited and patterned using microfabrication technology.
  • surface chloridation of gold generating electrodes was observed during the positive potential region of water electrolysis. This problem should be alleviated by replacing the gold generating and counter electrodes with platinum.
  • a titanium platinum layer will serve as both electrodes and wiring leads.
  • gold can be electroplated (for the working electrode) and silver (for the reference electrode) onto the platinum layer.
  • iridium oxide will also be plated.
  • the devices are designed so that the electroplating steps are self-aligning, and no additional photopatterning will be required. These procedures have already been established (Marzouk, 1998).
  • the preferred permeable membrane material is p-HEMA covered with polystyrene or collodion (Kreuzer, 1980).
  • a patient presents with an unresectable lung cancer (adenocarcinoma or squamous cell).
  • the conventional accepted treatment is a combination of radiation and chemotherapy.
  • the radiation is given everyday, Monday through Friday, and the chemotherapy (taxol and cisplatin) are administered either once a week in low doses or every three weeks in higher doses. All patients are treated in substantially the same manner and the expected response rate is between 50-75%. Therapy is not individualized despite the fact that it is known that oxygen levels, pH, and particularly, cell doubling times, may vary widely between patients.
  • the sensors can be positioned in situ in the tumor at different penetration depths or across different regions of the tumor to provide regional specific information.
  • Specific values or oxygen, pH, and cell proliferation can be established either prior to initiation of treatment by a predictive statistical norm in an established data base, or during initial treatment to define relative values, the specific values are identified as either a " go" for treatment or a " no go” for treatment to determine when and if a treatment should be commenced.
  • a monitoring algorithm can be used to quantify important values of variables and an affirmative attempt can be made to correct each variable to reach or approximate the desired specific levels at treatment. For example, to manipulate the tumor to achieve oxygenation of about 50-52mm Hg over a substantial volume of the tumor, as well as to exhibit a lower tumor pH of about 6.8, and to stimulate or identify and deliver during periods of increased cell proliferation.
  • each variable will be monitored to determine an appropriate time (associated with a favorable treatment period) to deliver the next dose of radiation and/or chemotherapy.
  • each patient is monitored at least four times each day following treatment to establish a specific response pattern for an individual patient. Utilizing this ongoing, periodic monitoring approach can allow delivery of any cytotoxic agent in a more precise and favorable manner and/or to withhold treatment during tumor treatment resistant periods. It is preferably to treat when all variables indicate that the tumor is vulnerable such as when there is an indication of high oxygenation level, low pH, and increased cell proliferation. It the variables do not synchronize to indicate a favorable index at the same time, then a statistical regression analysis can be identified to define an appropriate treatment time.
  • hyperthermia and/or other treatments can be incorporated into the treatment protocol, especially in tumors exhibiting a high hypoxic fraction. This can allow for increased cell kill, after which the kinetics of the tumor will change and allow for more precise delivery of the radiation and/or chemotherapy.
  • the individualized treatment will allow the delivery of cytotoxic agents at a favorable treatment time to achieve increased tumor cell kill, and thereby increase the response of the tumor to the treatment. In this example, when a satisfactory response has been obtained, the tumor can be removed.
  • the individualization of therapy can now be instituted based on obtaining information on the dynamic changes within each individual patient's tumor.
  • This information should lead to increase tumor cell kill, increased survival and decreased morbidity. This should translate into a decrease in the cost of treating patients by a decrease in morbidity and therefore less hospitalization; increase the effectiveness of cytotoxic agents by allowing for delivery of increased dose or even a decrease in the dose through more efficient timing of delivery of the cytotoxic.
  • the present invention can monitor and provide information on dynamic changes occurring within a tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99950017A 1998-09-30 1999-09-29 Methods, systems, and associated implantable devices for dynamic monitoring of tumors Expired - Lifetime EP1117328B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07016983A EP1867275B1 (en) 1998-09-30 1999-09-29 Systems comprising implantable devices for dynamic monitoring of tumors
DK07016983.4T DK1867275T3 (da) 1998-09-30 1999-09-29 Systemer med implanterbare aooarater til dynamisk overvågning af tumorer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10244798P 1998-09-30 1998-09-30
US102447P 1998-09-30
PCT/US1999/022638 WO2000018294A1 (en) 1998-09-30 1999-09-29 Methods, systems, and associated implantable devices for dynamic monitoring of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07016983A Division EP1867275B1 (en) 1998-09-30 1999-09-29 Systems comprising implantable devices for dynamic monitoring of tumors

Publications (2)

Publication Number Publication Date
EP1117328A1 EP1117328A1 (en) 2001-07-25
EP1117328B1 true EP1117328B1 (en) 2008-09-17

Family

ID=22289894

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07016983A Expired - Lifetime EP1867275B1 (en) 1998-09-30 1999-09-29 Systems comprising implantable devices for dynamic monitoring of tumors
EP99950017A Expired - Lifetime EP1117328B1 (en) 1998-09-30 1999-09-29 Methods, systems, and associated implantable devices for dynamic monitoring of tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07016983A Expired - Lifetime EP1867275B1 (en) 1998-09-30 1999-09-29 Systems comprising implantable devices for dynamic monitoring of tumors

Country Status (10)

Country Link
EP (2) EP1867275B1 (da)
JP (1) JP4365531B2 (da)
AT (2) ATE490725T1 (da)
AU (1) AU763446B2 (da)
CA (1) CA2341724C (da)
DE (2) DE69943029D1 (da)
DK (2) DK1117328T3 (da)
ES (1) ES2316193T3 (da)
PT (1) PT1117328E (da)
WO (1) WO2000018294A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261597B2 (en) 2018-06-01 2022-03-01 Abram Joze Head for a 3D printer and a method of using the same

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20050103624A1 (en) 1999-10-04 2005-05-19 Bhullar Raghbir S. Biosensor and method of making
US20010027384A1 (en) * 2000-03-01 2001-10-04 Schulze Arthur E. Wireless internet bio-telemetry monitoring system and method
US8909325B2 (en) 2000-08-21 2014-12-09 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7011814B2 (en) * 2001-04-23 2006-03-14 Sicel Technologies, Inc. Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject
US20030181794A1 (en) 2002-01-29 2003-09-25 Rini Christopher J. Implantable sensor housing, sensor unit and methods for forming and using the same
US7736309B2 (en) * 2002-09-27 2010-06-15 Medtronic Minimed, Inc. Implantable sensor method and system
US7244264B2 (en) 2002-12-03 2007-07-17 Roche Diagnostics Operations, Inc. Dual blade lancing test strip
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
JP4607859B2 (ja) 2003-02-19 2011-01-05 サイセル・テクノロジーズ，インコーポレイテッド 蛍光分析物と連動して作動するインビボ蛍光センサ、システム及び関連方法
DK1620714T3 (da) * 2003-04-15 2014-03-31 Senseonics Inc System og fremgangsmåde til at svække indvirkningen af omgivende lys på en optisk sensor
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US9470801B2 (en) 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
US7968851B2 (en) 2004-01-13 2011-06-28 Spectrum Dynamics Llc Dynamic spect camera
WO2008010227A2 (en) 2006-07-19 2008-01-24 Spectrum Dynamics Llc Imaging protocols
CA2556331A1 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
WO2005112895A2 (en) 2004-05-20 2005-12-01 Spectrum Dynamics Llc Ingestible device platform for the colon
EP1778957A4 (en) 2004-06-01 2015-12-23 Biosensors Int Group Ltd OPTIMIZING THE MEASUREMENT OF RADIOACTIVE EMISSIONS IN SPECIFIC BODY STRUCTURES
JP3950977B2 (ja) * 2004-06-25 2007-08-01 国立大学法人東北大学 体内埋め込み型リアルタイム式マイクロ線量計装置ならびに測定方法
US9943274B2 (en) 2004-11-09 2018-04-17 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
EP2510874A3 (en) * 2005-03-29 2012-11-28 Martin Roche Biometric sensor
EP1868485B1 (en) * 2005-04-15 2016-06-08 Surgisense Corporation Surgical instruments with sensors for detecting tissue properties, and systems using such instruments
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8894974B2 (en) 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US9275451B2 (en) 2006-12-20 2016-03-01 Biosensors International Group, Ltd. Method, a system, and an apparatus for using and processing multidimensional data
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
EP1972275B1 (de) * 2007-03-20 2015-10-28 Roche Diagnostics GmbH System zur in-vivo Messung einer Analytkonzentration
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
WO2010055455A1 (en) * 2008-11-11 2010-05-20 Koninklijke Philips Electronics N.V. Medical device comprising a probe for measuring temperature data in a patient's tissue
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
JP5700577B2 (ja) * 2009-06-26 2015-04-15 シアナ メディカル，インク． 身体内のマーカあるいは組織構造を位置決めする装置、システム及び方法
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc ANALYTICAL SUBSTANCE MONITORING SYSTEM AND METHODS OF MANAGING ENERGY AND NOISE
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9211185B2 (en) 2012-06-13 2015-12-15 Elwha Llc Breast implant with analyte sensors and internal power source
US8808373B2 (en) 2012-06-13 2014-08-19 Elwha Llc Breast implant with regionalized analyte sensors responsive to external power source
US9144489B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with covering, analyte sensors and internal power source
US9144488B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with analyte sensors responsive to external power source
US8790400B2 (en) 2012-06-13 2014-07-29 Elwha Llc Breast implant with covering and analyte sensors responsive to external power source
US8795359B2 (en) 2012-06-13 2014-08-05 Elwha Llc Breast implant with regionalized analyte sensors and internal power source
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
JP6554089B2 (ja) 2013-03-19 2019-07-31 サージセンス コーポレイション 組織酸素化の測定用の器具、システムおよびメソッド
JP6512623B2 (ja) * 2014-02-07 2019-05-15 国立大学法人北海道大学 吸収線量測定システムおよび測定装置および方法
JP6385740B2 (ja) 2014-07-04 2018-09-05 ルネサスエレクトロニクス株式会社 電子装置およびその製造方法
CN104970806B (zh) * 2015-07-12 2017-08-04 北京泱深生物信息技术有限公司 一种用于癌症复发实时动态监测的智能设备
CN111132604B (zh) * 2017-09-13 2023-04-04 豪洛捷公司 无线主动监测植入物系统
GB2566463A (en) * 2017-09-13 2019-03-20 Univ Southampton pH Sensor and Calibration method
CN113692249A (zh) * 2019-03-07 2021-11-23 普罗赛普特生物机器人公司 用于持续的患者监控和智能治疗的植入物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219558C2 (de) * 1982-05-25 1986-10-23 Norbert H.L. Dr.-Ing. 5173 Aldenhoven Koster Vorrichtung zur Bestimmung der lokalen Temperatur in lebendem Gewebe
JPS61146230A (ja) * 1984-12-19 1986-07-03 東洋通信機株式会社 係止具を設けた生体内埋込みセンサ
JPS62102733A (ja) * 1985-10-31 1987-05-13 東洋通信機株式会社 生体内温度検出表示装置
IL86470A (en) * 1988-05-23 1994-11-28 E M T Electro Magnetic Technol Means and method for temperature control from a distance
JP2762283B2 (ja) * 1988-10-31 1998-06-04 東洋通信機株式会社 生体内埋め込みセンサ
DE3932428A1 (de) * 1989-09-28 1991-04-11 Argumens Gmbh Vorrichtung zur drahtlosen messung einer lokalen physikalischen groesse
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
DE4341903A1 (de) * 1993-12-09 1995-06-14 Josef Prof Dr Rer Nat Binder Implantierbares telemetrisches Endosystem
US5544661A (en) * 1994-01-13 1996-08-13 Charles L. Davis Real time ambulatory patient monitor
US5593430A (en) * 1995-01-27 1997-01-14 Pacesetter, Inc. Bus system for interconnecting an implantable medical device with a plurality of sensors
US5720771A (en) 1995-08-02 1998-02-24 Pacesetter, Inc. Method and apparatus for monitoring physiological data from an implantable medical device
US5833603A (en) * 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
WO1997036192A1 (de) * 1996-03-27 1997-10-02 Paul Scherrer Institut Vorrichtung und verfahren zur positionsbestimmung
US5814089A (en) * 1996-12-18 1998-09-29 Medtronic, Inc. Leadless multisite implantable stimulus and diagnostic system
JP4157168B2 (ja) * 1997-03-27 2008-09-24 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ 身体のパラメータを監視及び又はそれに作用するための植込型装置のシステム
CA2294610A1 (en) * 1997-06-16 1998-12-23 George Moshe Katz Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods
JP2000005136A (ja) * 1998-06-26 2000-01-11 Nippon Telegr & Teleph Corp <Ntt> 温度測定装置およびインプラント
US9472410B2 (en) 2014-03-05 2016-10-18 Applied Materials, Inc. Pixelated capacitance controlled ESC

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261597B2 (en) 2018-06-01 2022-03-01 Abram Joze Head for a 3D printer and a method of using the same

Also Published As

Publication number Publication date
JP2002525153A (ja) 2002-08-13
ES2316193T3 (es) 2009-04-01
AU763446B2 (en) 2003-07-24
CA2341724A1 (en) 2000-04-06
CA2341724C (en) 2010-12-21
AU6276499A (en) 2000-04-17
PT1117328E (pt) 2008-12-02
DE69939592D1 (de) 2008-10-30
ATE408369T1 (de) 2008-10-15
DK1867275T3 (da) 2011-04-04
EP1867275A2 (en) 2007-12-19
DK1117328T3 (da) 2009-01-19
JP4365531B2 (ja) 2009-11-18
WO2000018294A1 (en) 2000-04-06
EP1867275A3 (en) 2008-04-09
EP1117328A1 (en) 2001-07-25
ATE490725T1 (de) 2010-12-15
DE69943029D1 (de) 2011-01-20
EP1867275B1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
EP1117328B1 (en) Methods, systems, and associated implantable devices for dynamic monitoring of tumors
US7756568B2 (en) Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
CN102469965B (zh) 分析物监测装置和使用方法
CN102472719B (zh) 分析物监测装置和使用方法
US10478108B2 (en) Analyte monitoring device and methods of use
US20190246957A1 (en) Tissue implantable sensor with hermetically sealed housing
JP5674777B2 (ja) 分析物モニタリング装置および使用方法
ES2869281T3 (es) Dispositivo de monitorización de analitos
JP2002513602A (ja) 分析物モニタシステムおよびその使用方法
JP2011136186A (ja) 検体監視装置、及びディジタル信号の伝送方法
Black et al. Integrated sensor-telemetry system for in vivo glucose monitoring
CN110831500A (zh) 医疗系统

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KERMANI, BAHRAM, GHAFFARZADEH, DR.

Inventor name: MUELLER, JEFFREY

Inventor name: HALL, LESTER, C.

Inventor name: NAGLE, H., TROY

Inventor name: SCARANTINO, CHARLES, W.

17Q First examination report despatched

Effective date: 20050603

17Q First examination report despatched

Effective date: 20050603

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RIN2 Information on inventor provided after grant (corrected)

Inventor name: KERMANI, BAHRAM, GHAFFARZADEH, DR.

Inventor name: MUELLER, JEFFREY

Inventor name: HALL, LESLIE, C.

Inventor name: NAGLE, H., TROY

Inventor name: SCARANTINO, CHARLES, W.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69939592

Country of ref document: DE

Date of ref document: 20081030

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20081118

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BRAUNPAT BRAUN EDER AG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2316193

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090618

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20090925

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090924

Year of fee payment: 11

Ref country code: FI

Payment date: 20090930

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20091002

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20091001

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20091026

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081218

BERE Be: lapsed

Owner name: NORTH CAROLINA STATE UNIVERSITY

Effective date: 20100930

Owner name: SICEL TECHNOLOGIES, INC.

Effective date: 20100930

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20110329

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110401

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110329

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20120224

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120302

Year of fee payment: 13

Ref country code: SE

Payment date: 20120228

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120302

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 408369

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120227

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120929

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20140929

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140917

Year of fee payment: 16

Ref country code: GB

Payment date: 20140929

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140929

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69939592

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150929

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160401

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150929

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930